score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		MEL-IPI_Pat83	MEL-IPI_Pat83-Tumor-SM-53U2W	
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.V176M	0.171	386.0	0.0	0.0																Investigate Actionability	0.0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	DNMT3A p.V176M (Missense)		MEL-IPI_Pat83	MEL-IPI_Pat83-Tumor-SM-53U2W	MEL-IPI_Pat83-Normal-SM-53U56
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		MEL-IPI_Pat83	MEL-IPI_Pat83-Tumor-SM-53U2W	
Biologically Relevant				Copy Number	RUNX1T1	Amplification				0.0	0.0																					0				RUNX1T1 Amplification		MEL-IPI_Pat83	MEL-IPI_Pat83-Tumor-SM-53U2W	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: ESRP1 Amplification, MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat83		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.581																									0				COSMIC Signature (version 2) 1 (58%)		MEL-IPI_Pat83		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.417																									0				COSMIC Signature (version 2) 7 (42%)		MEL-IPI_Pat83		
